Upon transfer into CD19 tumor-bearing mice, Akti-treated CD8 + CD19CAR T cells efficiently inhibited tumor growth and induced long-term survival as a result of improved antitumor activity and/or expansion. The gene discussed is CD8A; the disease is neoplasm.